摘要
肾细胞癌(RCC)的治疗策略研究在过去十多年取得了实质性进展,从细胞因子到靶向治疗以及新型的免疫调节药物等,RCC患者的生存率和预后改善显著。目前,以血管内皮生长因子、哺乳动物雷帕霉素靶蛋白、程序性细胞死亡受体1等为靶点的药物已获批用于RCC的一线和二线治疗。但由于肿瘤的异质性和耐药性不断进展,完全持久反应的病例较少,RCC的治疗仍面临诸多挑战。将上述治疗药物联合的用药方案能最大限度地提高临床疗效并降低毒副作用,达到协同抗癌的治疗目标。此外,基于RCC特异性基因组特征及其与耐药性发展相关的靶基因或替代途径的个体化治疗方案可能成为未来RCC治疗的新方向。
Substantial progress has been made in the treatment of renal cell cancer(RCC)over the past decade.The transitions from cytokines to targeted therapy,as well as new immunomodulatory drugs,has significantly improved the survival rate and prognosis of the patients with RCC.Drugs targeting vascular endothelial growth factor,mammalian target of rapamycin,programmed cell death receptor 1 etc.,have been approved for the first and second line therapy in RCC.However,as the progress of tumor heterogeneity and drug resistance,complete durable tumor responses are rare,and the management of RCC remains a therapeutic challenge.The combination of the above drugs can maximally improve the curative effect and reduce the adverse effects to achieve the therapeutic goal of synergetic anti-tumor effect.In addition,individualized treatment strategies based on RCC specific genomic features and their target genes or alternative pathways associated with the development of drug resistance may be developed as new directions for RCC treatment in the coming years.
作者
赵广宁
李黎明
ZHAO Guangning;LI Liming(Department of Urology,General Hospital of Tianjin Medical University,Tianjin 300052,China)
出处
《医学综述》
CAS
2021年第8期1545-1550,共6页
Medical Recapitulate
关键词
肾癌
靶向治疗
免疫调节药物
Renal cell carcinoma
Targeted therapy
Immunomodulatory drugs
